Exelixis (EXEL) Set to Release Earnings on Thursday

Exelixis (NASDAQ:EXEL) is projected to release its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Exelixis to post earnings of $0.8870 per share and revenue of $646.51 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 5:00 PM ET.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The company had revenue of $628.69 million for the quarter, compared to analysts’ expectations of $636.40 million. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the business earned $0.75 earnings per share. On average, analysts expect Exelixis to post $3.19 EPS for the current fiscal year and $3.71 EPS for the next fiscal year.

Exelixis Trading Up 0.4%

Exelixis stock opened at $65.35 on Wednesday. Exelixis has a 1 year low of $36.00 and a 1 year high of $65.58. The firm’s 50 day moving average price is $58.57 and its 200-day moving average price is $50.57.

Insider Transactions at Exelixis

In related news, Director Mary Beckerle sold 9,812 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the transaction, the director directly owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

EXEL has been the subject of a number of research reports. Barclays upped their target price on shares of Exelixis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 14th. Citizens Jmp lifted their price target on shares of Exelixis from $55.00 to $65.00 and gave the company a “market outperform” rating in a report on Monday, October 19th. UBS Group set a $55.00 price target on shares of Exelixis in a research note on Monday, August 3rd. Truist Financial boosted their price target on shares of Exelixis from $52.00 to $54.00 and gave the stock a “hold” rating in a research note on Wednesday, October 7th. Finally, Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $51.50.

About Exelixis

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.